Evidence map›Paper›PMID 28157214›Full record

ArticleBlood cancer journal2017

Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia.

Z Chen, L J Medeiros, H M Kantajian, L Zheng, Z Gong, K P Patel, H Xiong, W Wang, J E Cortes, S Hu

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. [How I treat pediatric chronic myeloid leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Chronic Myeloid Leukemia: Beyond BCR-ABL1.Current hematologic malignancy reports · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Z ChenDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
L J MedeirosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
H M KantajianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
L ZhengDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Z GongDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
K P PatelDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
H XiongDepartment of Hematology, Shanghai Xuhui Central Hospital, Shanghai, China.
W WangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J E CortesDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S HuDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultAgedAged, 80 and overAntineoplastic AgentsBlast CrisisFemaleHematopoietic Stem Cell TransplantationHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedPrognosisProtein Kinase InhibitorsTranscriptomeTransplantation, HomologousAntineoplastic AgentsProtein Kinase Inhibitors

Identifiers

PMID28157214
PMCPMC5386338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.